(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 6 February 2003 (06.02.2003)

PCT

(10) International Publication Number WO 03/010333 A3

(51) International Patent Classification7: 15/65, C12Q 1/68

C12N 15/09,

- (74) Agent: BERESKIN & PARR; 40 King Street West, 40th Floor, Toronto, Ontario M5H 3Y2 (CA).
- (21) International Application Number: PCT/CA02/01160
- (22) International Filing Date: 24 July 2002 (24.07.2002)
- (25) Filing Language:

English

(26) Publication Language:

English

- (30) Priority Data: 60/307,461
- 24 July 2001 (24.07.2001) US
- (71) Applicant (for all designated States except US): AFFINIUM PHARMACEUTICALS INC. [CA/CA]; 100 University Λνεοιιε, 10th Floor, South Tower, Toronto, Ontario M5J 1V6 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): AWREY, Donald, E. [CA/CA]; 2211 Stir Crescent, Mississauga, Ontario L4Y 3V2 (CA). GREENBLATT, Jack [CA/CA]; 141 Highbourne Road, Toronto, Ontario M5P 2J8 (CA).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, II., IN, IS, JP, KE, KG, KP, KR, KZ, I.C, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report


VN, YU, ZA, ZM, ZW.

 before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

[Continued on next page]

(54) Title: METHODS FOR GENE DISRUPTION AND USES THEREOF

Strategy for Gene Disruption



(57) Abstract: The present invention relates to compositions and methods for in-frame disruption of a gene sequence by homologous recombination. The present invention may be used in certain embodiments to disrupt a gene without causing any downstream effects on non-target sequences. In certain embodiments, the inventive methods may be used to identify and/or characterize products encoded by essential genes, conditionally essential genes, and non-essential genes.

0.03/010333 A3

(88) Date of publication of the international search report: 30 October 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

In mail Application No PCT/CA 02/01160

A. CLASS IPC 7	SIFICATION OF SUBJECT MATTER C12N15/09 C12N15/65 C12Q1/6	8	
Appording	to International Design Character (ICC) and both making the second		
	to International Patent Classification (IPC) or to both national classifi s SEARCHED	cation and IPC	
Minimum d	ocumentation searched (classification system followed by classifica	tion symbols)	
IPC 7	C12N C12Q		
Documenta	ation searched other than minimurn documentation to the extent that	such documents are included in the fields s	earched
Electronic o	data base consulted during the international search (name of data b	ase and, where practical, search terms used	1)
EPO-In	ternal, WPI Data, PAJ, BIOSIS, MEDL	INE, EMBASE	
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the re	elevant passages	Relevant to claim No.
X	LINK A J ET AL: "METHODS FOR GE PRECISE DELETIONS AND INSERTIONS GENOME OF WILD-TYPE ESCHERICHIA APPLICATION TO OPEN READING FRAM CHARACTERIZATION" JOURNAL OF BACTERIOLOGY, WASHING US, vol. 179, no. 20, October 1997 (pages 6228-6237, XP000890089 ISSN: 0021-9193 abstract page 6229, column 1, paragraph 1 page 6229, column 2, paragraph 7 6230, column 2; figure 1 page 6231, column 1, paragraph 3 6234, column 1, paragraph 1 page 6235, column 1, paragraph 3 6236, column 1, paragraph 3	IN THE COLI: E TON, DC, 1997-10), -page -page -page	1-29
X Furth	er documents are listed in the continuation of box C.	χ Patent family members are listed	in annex.
° Special cat	tegories of cited documents ;	"T" later document published after the inte	rnational filing date
A document defining the general state of the art which is not considered to be of particular relevance inventions. *E* certain decument that published as a refer the interestinal.			the application but cory underlying the
filing da	ate nt which may throw doubts on priority claim(s) or	"X" document of particular relevance; the c cannot be considered novel or cannot involve an inventive step when the do	be considered to
Which i	s cited to establish the publication date of another or other special reason (as specified)	"Y" document of particular relevance: the c	laimed invention
"O" document referring to an oral disclosure, use, exhibition or other means clean of the considered to involve an in document referring to an oral disclosure, use, exhibition or other means ments, such combination being obvious			re other such docu-
"P" documer	nt published prior to the international filing date but an the priority date claimed	in the art. *&" document member of the same patent i	•
Date of the a	ctual completion of the international search	Date of malling of the international sea	
	2 September 2003	19/09/2003	
Name and m	railing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2	Authorized officer	
	NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,	Tilkorn A-C	

1

I mal Application No
PCT/CA 02/01160

- /-		PCT/CA 02/01160
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 44906 A (ELITRA PHARMACEUTICALS INC) 3 August 2000 (2000-08-03) page 13, line 28 -page 15, line 18; example 5 page 16, line 15 - line 29	1-29
X	WENDLAND J ET AL: "PCR-based gene targeting in the filamentous fungus Ashbya gossypii" GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 242, no. 1-2, January 2000 (2000-01), pages 381-391, XP004196539 ISSN: 0378-1119 abstract page 382, column 1, paragraph 2 -page 386, column 1, paragraph 1 page 386, column 2, paragraph 2 -page 390, column 1, paragraph 4; figures 1-6; table 2	1-29
A	LORENZ M C ET AL: "Gene disruption with PCR products in Saccharomyces cerevisiae" GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 158, no. 1, 1995, pages 113-117, XP004206649 ISSN: 0378-1119 the whole document	1-29
A	ZAMBROWICZ B P ET AL: "Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 392, 9 April 1998 (1998-04-09), pages 608-611, XP002111633 ISSN: 0028-0836 the whole document	1–29
A	WILES M V ET AL: "Establishment of a gene-trap sequence tag library to generate mutant mice from embryonic stem cells" NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 24, January 2000 (2000-01), pages 13-14, XP002180070 ISSN: 1061-4036 the whole document	1-29
4	WO 99 29837 A (EUROP LAB MOLEKULARBIOLOG; ZHANG YOUMING (DE); BUCHHOLZ FRANK (DE)) 17 June 1999 (1999-06-17) the whole document	1-29
	-/- -	

onal Application No
PCT/CA 02/01160

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.						
Category °	Citation of document, with indication, where appropriate, of the relevant passages	nelevani lo cialii iyo.				
>,Х	WO 01 60975 A (BOONE CHARLES; BUSSEY HOWARD (CA); JIANG BO (CA); ROEMER TERRY (CA) 23 August 2001 (2001-08-23) abstract page 10, line 7 - line 20 page 16, line 10 -page 18, line 14 page 23, line 7 -page 26, line 14 page 32, line 28 -page 35, line 8; table II page 93, line 1 -page 95, line 10 page 109, line 9 -page 110, line 34; figure 2	1–29				
•						

international application No. PCT/CA 02/01160

INTERNATIONAL SEARCH REPORT

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: 1-29 (partially) 30 (completely) because they relate to subject matter not required to be searched by this Authority, namely: See FURTHER INFORMATION sheet PCT/ISA/210
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
з. 🔲	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 1-29 encompass methods that involve an invasise step i.e. the provision of a host cell, the search has been carried out and based on methods carried out on isolated cells.

Continuation of Box I.1

Claims Nos.: 1-29 (partially), 30 (completely)

Rule 39.1(v) PCT - Presentation of information Rule 39.1(iv) PCT -Claims 1-29 encompass methods that involve an in vivo step carried out on a human or animal body, namely the provision of a host cell of an organism (step (a)).

Rule 39.1(v) PCT - Presentation of information - Claim 30 is directed to a database, which is mere presentation of information completely lacking technical features

Information on patent family members

ir onal Application No
PCT/CA 02/01160

	atent document d in search report		Publication date		Patent family member(s)	Publication date
WO	0044906	A	03-08-2000	AU	3584500 A	18-08-2000
				CA	2360085 A1	03-08-2000
				EΡ	1149166 A2	31-10-2001
				EP	1178052 A2	06-02-2002
				JP	2002535007 T	22-10-2002
				MO	0044906 A2	03-08-2000
				US	2002045592 A1	18-04-2002
MO	9929837	 А	17-06-1999	AT	242320 T	15-06-2003
				ΑU	752105 B2	05-09-2002
				AU	1877199 A	28-06-1999
				CA	2312474 A1	17-06-1999
				DE	69815384 D1	10-07-2003
				WO	9929837 A2	17-06-1999
				ΕP	1291420 A1	12-03-2003
	•			ΕP	1034260 A2	13-09-2000
				JР	2002503448 T	05-02-2002
				US	2003036198 A1	20-02-2003
				US	6509156 B1	21-01-2003
WO	0160975	Α	23-08-2001	AU	4320401 A	27-08-2001
				CA	2398861 A1	23-08-2001
				ΕP	1292668 A2	19-03-2003
				JP	2003523197 T	05-08-2003
				WO	0160975 A2	23-08-2001